BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 36434147)

  • 21. Impact of genetic variation in breast cancer resistance protein (BCRP/ABCG2) on sunitinib pharmacokinetics.
    Mizuno T; Fukudo M; Terada T; Kamba T; Nakamura E; Ogawa O; Inui K; Katsura T
    Drug Metab Pharmacokinet; 2012; 27(6):631-9. PubMed ID: 22673043
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetic role of protein binding of mycophenolic acid and its glucuronide metabolite in renal transplant recipients.
    de Winter BC; van Gelder T; Sombogaard F; Shaw LM; van Hest RM; Mathot RA
    J Pharmacokinet Pharmacodyn; 2009 Dec; 36(6):541-64. PubMed ID: 19904584
    [TBL] [Abstract][Full Text] [Related]  

  • 23. C-440T/T-331C polymorphisms in the UGT1A9 gene affect the pharmacokinetics of mycophenolic acid in kidney transplantation.
    Baldelli S; Merlini S; Perico N; Nicastri A; Cortinovis M; Gotti E; Remuzzi G; Cattaneo D
    Pharmacogenomics; 2007 Sep; 8(9):1127-41. PubMed ID: 17924828
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetic modeling of enterohepatic circulation of mycophenolic acid in renal transplant recipients.
    Colom H; Lloberas N; Andreu F; Caldés A; Torras J; Oppenheimer F; Sanchez-Plumed J; Gentil MA; Kuypers DR; Brunet M; Ekberg H; Grinyó JM
    Kidney Int; 2014 Jun; 85(6):1434-43. PubMed ID: 24402086
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ABCG2 c.421C>A polymorphism alters nifedipine transport to breast milk in hypertensive breastfeeding women.
    Malfará BN; Benzi JRL; de Oliveira Filgueira GC; Zanelli CF; Duarte G; de Carvalho Cavalli R; de Moraes NV
    Reprod Toxicol; 2019 Apr; 85():1-5. PubMed ID: 30659932
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association Study of a Functional Variant on ABCG2 Gene with Sunitinib-Induced Severe Adverse Drug Reaction.
    Low SK; Fukunaga K; Takahashi A; Matsuda K; Hongo F; Nakanishi H; Kitamura H; Inoue T; Kato Y; Tomita Y; Fukasawa S; Tanaka T; Nishimura K; Uemura H; Hara I; Fujisawa M; Matsuyama H; Hashine K; Tatsugami K; Enokida H; Kubo M; Miki T; Mushiroda T
    PLoS One; 2016; 11(2):e0148177. PubMed ID: 26914831
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of ABCG2 genotypes on the pharmacokinetics of A771726, an active metabolite of prodrug leflunomide, and association of A771726 exposure with serum uric acid level.
    Kim KA; Joo HJ; Park JY
    Eur J Clin Pharmacol; 2011 Feb; 67(2):129-34. PubMed ID: 20972558
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Time-related clinical determinants of long-term tacrolimus pharmacokinetics in combination therapy with mycophenolic acid and corticosteroids: a prospective study in one hundred de novo renal transplant recipients.
    Kuypers DR; Claes K; Evenepoel P; Maes B; Coosemans W; Pirenne J; Vanrenterghem Y
    Clin Pharmacokinet; 2004; 43(11):741-62. PubMed ID: 15301578
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mycophenolic acid pharmacokinetics during maintenance immunosuppression in African American and Caucasian renal transplant recipients.
    Tornatore KM; Sudchada P; Dole K; DiFrancesco R; Leca N; Gundroo AC; Danison RT; Attwood K; Wilding GE; Zack J; Forrest A; Venuto RC
    J Clin Pharmacol; 2011 Aug; 51(8):1213-22. PubMed ID: 21209244
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ABCG2 polymorphisms, 34G>A and 421C>A in a Korean population: analysis and a comprehensive comparison with other populations.
    Kim KA; Joo HJ; Park JY
    J Clin Pharm Ther; 2010 Dec; 35(6):705-12. PubMed ID: 21054463
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessment of Transporter Polymorphisms as a Factor in a BCRP Drug Interaction Study With Lanabecestat.
    Willis BA; Andersen SW; Ayan-Oshodi M; James DE; Liffick E; Hillgren K; Guo Y; Monk SA
    J Clin Pharmacol; 2020 Jan; 60(1):107-116. PubMed ID: 31378968
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association Between ABCG2, ABCB1, ABCC2 Efflux Transporter Single-Nucleotide Variants and Irinotecan Adverse Effects in Patients With Colorectal Cancer: A Real-Life Study.
    Barnett-Griness O; Rennert G; Lejbkowicz F; Pinchev M; Saliba W; Gronich N
    Clin Pharmacol Ther; 2023 Mar; 113(3):704-711. PubMed ID: 36537755
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of splicing-regulatory polymorphisms in ABCC2, ABCG2, and ABCB1 on methotrexate exposure in Chinese children with acute lymphoblastic leukemia.
    Li M; Kong XY; Wang SM
    Cancer Chemother Pharmacol; 2023 Jan; 91(1):77-87. PubMed ID: 36463535
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ABCG2 c.421C>A Is Associated with Outcomes after Severe Traumatic Brain Injury.
    Adams SM; Conley YP; Ren D; Okonkwo DO; Puccio AM; Dixon CE; Clark RSB; Kochanek PM; Empey PE
    J Neurotrauma; 2018 Jan; 35(1):48-53. PubMed ID: 28747144
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interindividual Regulation of the Breast Cancer Resistance Protein/
    Bircsak KM; Moscovitz JE; Wen X; Archer F; Yuen PYS; Mohammed M; Memon N; Weinberger BI; Saba LM; Vetrano AM; Aleksunes LM
    Drug Metab Dispos; 2018 May; 46(5):619-627. PubMed ID: 29386232
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Regression and Genomic Analyses on the Association Between Dose-Normalized Mycophenolic Acid Exposure and Absolute Neutrophil Count in Steroid-Free, De Novo Kidney Transplant Recipients.
    Kiang TKL; Partovi N; Shapiro RJ; Berman JM; Collier AC; Ensom MHH
    Clin Drug Investig; 2018 Nov; 38(11):1011-1022. PubMed ID: 30178220
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mycophenolic Acid and Its Metabolites in Kidney Transplant Recipients: A Semimechanistic Enterohepatic Circulation Model to Improve Estimating Exposure.
    Okour M; Jacobson PA; Ahmed MA; Israni AK; Brundage RC
    J Clin Pharmacol; 2018 May; 58(5):628-639. PubMed ID: 29329489
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Influence of CYP3A5 and MDR1(ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in Chinese renal transplant recipients.
    Rong G; Jing L; Deng-Qing L; Hong-Shan Z; Shai-Hong Z; Xin-Min N
    Transplant Proc; 2010 Nov; 42(9):3455-8. PubMed ID: 21094796
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Telmisartan pharmacokinetics in Japanese renal transplant recipients.
    Miura M; Satoh S; Inoue K; Saito M; Habuchi T; Suzuki T
    Clin Chim Acta; 2009 Jan; 399(1-2):83-7. PubMed ID: 18838068
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of cyclosporine withdrawal on mycophenolic acid pharmacokinetics in kidney transplant recipients with deteriorating renal function: preliminary report.
    Shipkova M; Armstrong VW; Kuypers D; Perner F; Fabrizi V; Holzer H; Wieland E; Oellerich M;
    Ther Drug Monit; 2001 Dec; 23(6):717-21. PubMed ID: 11802109
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.